| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_500d0b8aa59ea0f0d722a24c19f8fe5b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_76dde33e2161eac9f9544f51cc23b2d0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e896be16fc9f53a0842448c0d1f28fc6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ff81a650b70e913d3b2524b45e4c7320
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f05ee0420e297b84b12b6e6dcc261ff6 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-544
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-37 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-775
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-37
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 |
| filingDate |
2004-02-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1263d3c4847008c6781a977c6f7a035b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f8a0e9b9879af7ff21e1feeecd1bcef3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7f7a8c0ade360127ea770fd4354ec701
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5bc03379e75aeab576df197eaffd486b |
| publicationDate |
2006-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2004071420-A3 |
| titleOfInvention |
Compositions and methods for less immunogenic protein formulations |
| abstract |
Composition and methods are described for low immunogenic protein formulations. An example of such a protein is antihemophilic factor (FVIII). The composition generally includes the protein, polypeptide or peptide, one or more agents that bind to epitope domains of the proteins to forth a complex. Buffers containing salts may be used to stabilize this interaction. For example, Factor VIII and serine containing phospholipids in buffer salts containing Ca2+ and Na+ can be used to prepare protein-lipid structures. These complexes are useful for treatment of diseases such as Hemophilia. A method for the formation of novel non-liposomal structures is also disclosed. |
| priorityDate |
2003-02-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |